VEGF being an important pro-angiogenic molecule, is increased in various pathological conditions like proliferative diabetic retinopathy, rheumatoid arthritis3, psoriasis4 etc. Conventionally, VEGF is controlled by administration of anti-VEGF medications viz Bevacizumab, Ranibizumab, Pegaptanib and Aflibercept. The gene discussed is VEGFA; the disease is proliferative diabetic retinopathy.